GetTopicDetailResponse(id=381121865b7, topicName=中國(guó)批準(zhǔn), introduction=中國(guó)批準(zhǔn), content=null, image=null, comments=5, allHits=1363, url=https://h5.medsci.cn/topic?id=21865, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=98318, tagList=[TagDto(tagId=98318, tagName=中國(guó)批準(zhǔn))], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1744325, encodeId=24751e4432517, content=<a href='/topic/show?id=381121865b7' target=_blank style='color:#2F92EE;'>#中國(guó)批準(zhǔn)#</a>, objectTitle=中國(guó)批準(zhǔn)國(guó)產(chǎn)阿爾茨海默癥早診示蹤劑進(jìn)入III期臨床, objectType=article, longId=202931, objectId=45b2202931e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b2202931e6, replyNumber=0, likeNumber=129, createdTime=2021-04-10, rootId=0, userName=minlingfeng, userId=3ff835348916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b2202931e6, moduleTitle=中國(guó)批準(zhǔn)國(guó)產(chǎn)阿爾茨海默癥早診示蹤劑進(jìn)入III期臨床, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=45b2202931e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744324, encodeId=d6df1e4432430, content=<a href='/topic/show?id=381121865b7' target=_blank style='color:#2F92EE;'>#中國(guó)批準(zhǔn)#</a>, objectTitle=NMPA：中國(guó)批準(zhǔn)氘代藥物——氘代丁苯那嗪用于HD舞蹈病和成人遲發(fā)性運(yùn)動(dòng)障礙, objectType=article, longId=194389, objectId=ce3b1943891e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3b1943891e, replyNumber=0, likeNumber=88, createdTime=2020-06-22, rootId=0, userName=minlingfeng, userId=3ff835348916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3b1943891e, moduleTitle=NMPA：中國(guó)批準(zhǔn)氘代藥物——氘代丁苯那嗪用于HD舞蹈病和成人遲發(fā)性運(yùn)動(dòng)障礙, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ce3b1943891e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744323, encodeId=5ef01e4432324, content=<a href='/topic/show?id=381121865b7' target=_blank style='color:#2F92EE;'>#中國(guó)批準(zhǔn)#</a>, objectTitle=中國(guó)批準(zhǔn)將羅氏的白細(xì)胞介素-6單抗Actemra，用于控制新型冠狀病毒感染患者體內(nèi)的炎癥風(fēng)暴, objectType=article, longId=189445, objectId=ee8f189445fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee8f189445fd, replyNumber=0, likeNumber=130, createdTime=2020-06-07, rootId=0, userName=minlingfeng, userId=3ff835348916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee8f189445fd, moduleTitle=中國(guó)批準(zhǔn)將羅氏的白細(xì)胞介素-6單抗Actemra，用于控制新型冠狀病毒感染患者體內(nèi)的炎癥風(fēng)暴, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ee8f189445fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744321, encodeId=ff121e44321ae, content=<a href='/topic/show?id=381121865b7' target=_blank style='color:#2F92EE;'>#中國(guó)批準(zhǔn)#</a>, objectTitle=**學(xué)術(shù)期刊連發(fā)兩文，需謹(jǐn)慎對(duì)待中國(guó)批準(zhǔn)的治療阿爾茨海默新藥, objectType=article, longId=182578, objectId=92aa1825e838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92aa1825e838, replyNumber=0, likeNumber=100, createdTime=2020-06-17, rootId=0, userName=minlingfeng, userId=3ff835348916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92aa1825e838, moduleTitle=**學(xué)術(shù)期刊連發(fā)兩文，需謹(jǐn)慎對(duì)待中國(guó)批準(zhǔn)的治療阿爾茨海默新藥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=92aa1825e838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744322, encodeId=b31e1e443229e, content=<a href='/topic/show?id=381121865b7' target=_blank style='color:#2F92EE;'>#中國(guó)批準(zhǔn)#</a>, objectTitle=中國(guó)批準(zhǔn)本土生產(chǎn)的肺炎疫苗和HPV疫苗上市, objectType=article, longId=185526, objectId=45821855268b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45821855268b, replyNumber=0, likeNumber=135, createdTime=2020-12-17, rootId=0, userName=minlingfeng, userId=3ff835348916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45821855268b, moduleTitle=中國(guó)批準(zhǔn)本土生產(chǎn)的肺炎疫苗和HPV疫苗上市, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=45821855268b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
